logo-loader
RNS
IP Group PLC

IP Group PLC - Autifony signs deal with Jazz for up to $770m

RNS Number : 3717T
IP Group PLC
14 November 2023
 

FOR RELEASE ON

14 November 2023

Portfolio company Autifony signs global licencing deal worth up to $770m with Nasdaq's Jazz Pharmaceuticals

IP Group plc (LSE: IPO) ("IP Group" or "the Group"), which invests in breakthrough science and innovation companies with the potential to create a better future for all, is pleased to note that Autifony Therapeutics Ltd ("Autifony" or "the Company") has entered into an exclusive global licensing agreement with Nasdaq-listed Jazz Pharmaceuticals plc ("Jazz"). Through the agreement, Autifony, which is pioneering the development of novel pharmaceutical treatments for rare CNS disorders and other serious brain diseases, will discover and develop drug candidates targeting two different ion channel targets associated with neurological disorders.

 

Under the terms of the agreement, Autifony will receive an upfront payment from Jazz and is eligible to receive development, regulatory and commercial milestone payments across the two programmes. The upfront and milestone payments have a combined total value of up to $770m. Autifony is also eligible to receive tiered royalties on future net sales.

 

Autifony will lead drug discovery and preclinical development activities on the two targets. Subsequent to successful completion of such preclinical development, Jazz will lead all clinical development, manufacturing and regulatory activities and commercialisation.

 

IP Group has an undiluted beneficial holding in Autifony of 26.3%, valued at £4.6m. The directors will review the carrying value of Autifony, as usual, as part of the Group's Annual Results for 2023 in light of this transaction and all other relevant information. The directors currently anticipate a fair value gain of approximately £5m.

 

For more information, please contact:

 

IP Group plc

www.ipgroupplc.com

Liz Vaughan-Adams, Communications

+44 (0) 20 7444 0062/+44 (0) 7967 312125

Portland

Vic Wallin

Alex Donaldson

+44 (0) 7973 823119

+44 (0) 7516 729702

 

Notes for editors

 

About IP Group

 

IP Group accelerates the impact of science for a better future. As the most active UK based, early stage science investor, we develop and support some of the world's most exciting businesses in deeptech, life sciences and cleantech (led by Kiko Ventures). Through Parkwalk, the UK's largest growth EIS fund manager, we also back world-changing innovation emerging in leading universities and research institutions. Our specialist investment team combines sector expertise with an international approach. Together we have a strong track record of success, having backed high-profile companies including Oxford Nanopore Technologies plc, First Light Fusion, Hysata, and Oxbotica. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO. For more information, please visit our website at www.ipgroupplc.com.

 

About Autifony


Autifony Therapeutics is an independent UK based biotechnology company formed in 2011 as a spin-out from GSK,
which retains equity in the company. The Company is focused on the development of high value, novel medicines to treat serious diseases of the central nervous system.  It is funded by SV Health Investors, IP Group, Pfizer Ventures, International Biotechnology Trust PLC, and UCL Business plc.  For more information, please visit www.autifony.com.

ENDS

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAGZMMMNDRGFZG
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

Metals One, Arrow Exploration, IXICO, Ilika, IP Group - Small Cap Snapshot

Metals One PLC (AIM:MET1, FRA:HT7, OTCQB:MTOPF) has agreed to buy full ownership of South African gold and power business Lions Bay Resources for £6.5 million in shares. The key asset is the Barbrook Gold Mine, and the company is targeting first gold concentrate within six months of completion,...

4 weeks ago

3 min read